Xtherapeutics ApS: Financial statements 2024
CVR: 37384089
Source: annual report 2024, Danish Business Authority
01/07/2023 – 30/06/2024
Xtherapeutics ApS (CVR 37384089) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -14,323 and a net result of DKK -14,323 compared with DKK -17,084 the year before. Equity in the 2024 report amounted to DKK -18,439.
- Gross Profit
- DKK -14,323
- Profit/Loss
- DKK -14,323
- Equity
- DKK -18,439
- Total Assets
- DKK 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -14 t. | -14 t. | -18 t. | - |
| 2023 | - | -17 t. | -17 t. | -4 t. | - |
| 2022 | - | -9 t. | -14 t. | 13 t. | - |
| 2021 | - | - | -5 t. | -13 t. | - |
| 2020 | 0 | 0 | 0 | 1 | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout Xtherapeutics ApS
Xtherapeutics ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Xtherapeutics IVS and Vaccex IVS. The management consists of Thomas Lars Andresen. The company is owned by Jonas Rosager Henriksen, Anders Elias Hansen and TLA-HOLDING 2010 ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 0 compared with DKK -14,323 the year before. Equity in the 2025 report amounted to DKK -18,439.